Human blood monocyte-derived macrophages that had been cultured in medium containing human serum for 7 days degraded the abnormal very-low-density lipoproteins (VLDL) from the plasma of subjects with type III hyperlipoproteinaemia by two distinct saturable processes. One process was stimulated when cells from normal subjects were preincubated with lipoprotein-free medium, was inhibited by excess unlabelled low-density lipoproteins (LDL) and was absent from cells from subjects with homozygous familial hypercholesterolaemia; on these criteria it was identified as an LDL-receptor-dependent process. Degradation by the second process was of equal magnitude in both cell types and was unaffected by excess unlabelled LDL or acetylated LDL. The activity of this process was reduced when the cells were preincubated in lipoprotein-free medium. The abnormal VLDL from the plasma of cholesterol-fed rabbits were also degraded by this process, which was similar to that in mouse peritoneal macrophages mediated by the receptor for VLDL of 1l-electrophoretic mobility [Goldstein, Ho, Brown,
the same cells isolated from subjects with homozygous familial hypercholesterolaemia (FH) in whom there are no functional LDL receptors (Goldstein & Brown, 1977) .
In familial type III hyperlipoproteinaemia, a disease that is accompanied by premature atherosclerosis (Fredrickson et al., 1978) , an abnormal cholesterol-rich lipoprotein of f-mobility accumulates in the VLDL fraction in plasma. This lipoprotein is believed -to comprise the remnants of metabolism of chylomicrons or VLDL that fail to be cleared from the circulation in the normal way (Chait et al., 1977) due to two independent factors: first the presence in the lipoproteins of a genetic variant of apolipoprotein E (apoE2) (Utermann et al., 1977) that is not recognized by the LDL (apoB,E) receptor (Schneider et al., 1981) , and second, overloading of alternative removal mechanisms due to an increased rate of production of triacylglycerol-rich lipoproteins determined by a second genetic factor (Utermann et al., 1979) or by some other metabolic disturbance (Myant, 1981) . The abnormal VLDL in the plasma of type III subjects (type III VLDL) has properties in common with the abnormal fl-VLDL found in the plasma of animals fed a cholesterol-rich diet (Mahley, 1978) , and its uptake by macrophage cells may well be responsible for the massive deposition of cholesterol in the peripheral tissues and arterial wall of type III patients that also occurs in cholesterol-fed animals. Since this abnormal lipoprotein has many of the characteristics of normal remnant lipoproteins (Mj0s et al., 1975) , it is important to understand the mechanisms involved in its uptake and degradation by cells. In the present study we have examined the degradation of type III VLDL and rabbit fl-VLDL by monocytederived macrophages from normal subjects and from patients with homozygous FH, and by macrophages from the peritoneal cavity of mice.
Methods
Isolation and maintenance of cells Culture medium was adjusted to pH 7.4 and contained 100 units of penicillin/ml and 100 sg of streptomycin/ml. All incubations were performed at 37°C in an atmosphere of C02/air (1:19) in a humidified incubator. Human mononuclear cells were isolated from freshly drawn blood of five normal donors and from the buffy coat obtained during plasma exchange (Thompson et al., 1975) of two FH patients (homozygous, type IIa receptor-defective) by methods described previously (Knight & Soutar, 1982b) . Cells were seeded at a density of approx. 3 x 106 cells/well in Linbro Multidishes (Flow Laboratories, Irvine, Ayrshire, Scotland, U.K.), containing 1ml of RPMI-1640 medium (Gibco Europe) (20%, v/v) was added. Experiments were performed on day 7 or 8 after seeding. As described previously (Knight & Soutar, 1982a) Knight, unpublished work) .
Peritoneal macrophages were obtained from unstimulated CFLP mice, essentially by the method described by Cohn & Benson (1965) . Dulbecco's modified Eagle's medium (DME) containing 5 units of heparin/ml was injected into the peritoneal cavity and as much as possible withdrawn with a wide-gauge needle. Macrophages were collected by centrifugation at 400g for 10min and the pellet resuspended in DME medium containing 10% foetal-calf serum. Macrophages were dispensed at a concentration of 1 x 106 cells/well into 24mm-diameter Multidish wells containing a final volume of 1 ml of DME medium with 10% foetalcalf serum, and incubated at 37°C for 4h. Nonadherent cells were removed by washing with DME medium. Adherent cells were incubated in 1 ml of DME medium containing 10% foetal-calf serum or lipoprotein-deficient human serum (5mg of protein/ml) and the experiments were performed the next day. Each well then contained approx. 60ig of cell protein.
Lipoproteins LDL [density (p) = 1.019-1.055g/ml] was isolated from fresh plasma from normal healthy donors, labelled with Na125I (carrier-free; Amersham International) and acetylated with acetic anhydride as described previously (Soutar & Knight, 1982 (Soutar & Knight, 1982 Johnson (1979) . Protein and tetramethylurea-solubleprotein concentrations were determined using the method of Kane et al. (1975) .
All lipoproteins were stored sterile at 4°C and were dialysed for 2h against 100 vol. of Dulbecco's phosphate-buffered saline immediately before each experiment.
Experimental procedure
Human cells to be preincubated in non-autologous serum were washed twice with RPMI-1640 medium before the addition of fresh medium (1 ml/well) containing lipoprotein-deficient serum (5mg of protein/ml of medium) or the alternative whole serum (20%, v/v); preincubation was normally for 18-20h. Immediately before the experiments, human monocyte-derived macrophages and mouse peritoneal macrophages were washed twice with 1 ml of medium (RPMI-1640 for human cells; DME for mouse cells) and medium containing lipoprotein-deficient serum (2.5mg of protein/ml), and lipoproteins, labelled and unlabelled as indicated, were added to give a final volume of 0.5ml/well. The lipoprotein solutions did not account for more than 15% of the total volume. The cells were incubated for 4h at 37°C, after which lipoprotein degradation was determined from the amount of trichloroacetic acid-soluble, non-iodide radioactivity in the medium, as previously described (Soutar & Knight, 1982 Type III VLDL (pg of protein/ml) Fig. 1 . Degradation of type III VLDL by monocyte-derived macrophages from normal and FH subjects (a) Cells from normal (0) and FH (0) subjects were maintained in culture for 7 days in medium containing normal human serum (20%, v/v) . On the day of the experiment the cells were washed and incubated for 4h in medium containing lipoprotein-deficient serum to which was added 125I-labelled type III VLDL (sp. radioactivity 100c.p.m./mg of protein) to give the concentration indicated. (b) Cells from a normal subject were maintained in culture for 7 days in medium containing 20% (v/v) normal human serum, then washed and preincubated for 20h in either fresh medium containing lipoprotein-deficient serum (5mg of protein/ml) (A) or fresh medium containing FH serum (20%, v/v) (A) . After preincubation, the cells were washed and incubated with 125I-labelled type III VLDL as described above. Each point is the mean of values obtained in two experiments, which did not differ by more than 10%.
Monocyte-derived macrophages, from normal and FH subjects, that had been maintained in medium containing 20% (v/v) normal human serum were also able to degrade lipoproteins of p<1.006g/ml isolated from the serum of cholesterol-fed rabbits (rabbit fi-VLDL). Comparison of the degradation of this lipoprotein by normal and FH cells suggested that rabbit f,-VLDL was also degraded by two saturable processes in normal cells, one of which was dependent on the LDL receptor. As expected, therefore, preincubation of normal cells in lipoprotein-deficient medium increased the amount of rabbit ,B-VLDL degraded at each concentration of lipoprotein in the medium (Fig. 2a) (Figs. 3 and 4a) ; maximum degradation occurred with 15-20 g of lipoprotein/ml. In contrast, degradation of LDL by mouse cells under these conditions showed no evidence of saturability with concentrations of LDL as high as 50pg of lipoprotein protein/ml (Fig. 4b) five times as much rabbit j3-VLDL as type III VLDL (Table 2 ). This difference suggested that the processes for the degradation of type III VLDL and rabbit ,B-VLDL in the human cells had differ- (Fig. 5) ; the maximum inhibitory effect of type III VLDL was identical with the maximum effect of LDL, confirming that type III VLDL was taken up by the LDL receptor in these cells. In contrast with this, LDL and type III VLDL were not equally effective in inhibiting the degradation of 125I-labelled type III VLDL by normal cells (Fig. 6a) (Fig. 6b) .
Comparison of the effects of adding unlabelled type III VLDL on the degradation of '25I-labelled type III VLDL and 125I-labelled rabbit /3-VLDL confirmed that the processes in the human cells for the degradation of these lipoproteins were not identical with those in the mouse peritoneal macrophages. Unlabelled type III VLDL inhibited the degradation of 125I-labelled type III VLDL (Fig.  7a ) and 125I-labelled rabbit ,B-VLDL (Fig. 7b) (Fig. 7a) , it had much less effect on the degradation of 1 25I-labelled rabbit fi-VLDL- (Fig. 7b) . On the other hand, unlabelled rabbit fJ-VLDL (a 10-fold excess over the concentration of labelled lipoprotein) inhibited the degradation by mouse cells of both I25I-labelled type III VLDL and 1251-labelled rabbit fi-VLDL by approx. 70-80% (results not shown). Thus, although it is probable that in mouse cells, as in human, degradation of rabbit One possibility for the apparent lack of accumulation of cholesteryl esters when human monocytederived macrophages are incubated with type III VLDL is that lipoprotein lipase, known to be released from these cells in culture (Mahoney et al., 1982; Chait et al., 1982) , may hydrolyse the triacylglycerol content of the lipoprotein, thereby diluting the specific radioactivity of the [14C]oleate. To investigate this point, the absolute amount of cholesterol and cholesteryl ester present in FH monocyte-derived macrophages was determined after they had been incubated for 18 h in medium containing no serum to which nothing, LDL (50.ug of protein/ml), rabbit f3-VLDL ( Mahley et al., 1980) . The non-LDL-receptor-mediated process in human monocyte-derived macrophages has properties in common with this. However, they differ in that we found that the mouse cells degrade much more rabbit f3-VLDL than type III VLDL, and have an apparently greater affinity for rabbit fi-VLDL than for type III VLDL, whereas the process in the human cells did not appear to discriminate between the two lipoproteins. Whether this represents a real difference between the receptormediated process in the two cell types or whether it represents a minor species difference in specificity of the same receptor is not clear. Indeed, the specific requirements for uptake of a lipoprotein by this (Mahley, 1978; Myant, 1981) , they contain apoB48, the genetic variant of apoB synthesized by intestinal cells in animals (Wu & Windmueller, 1981) and found in human chylomicrons (Kane et al., 1980 
